Clinical Trials Directory
We are doing this study to research the genes of patients with lung cancer that has been or will be removed by surgery for a chance to get treatment in a clinical trial.
We are doing this study to compare the usual treatment alone (treatment with ipilimumab and nivolumab followed by nivolumab alone) to the usual treatment with ipilimumab and nivolumab, follwed by nivolumab and cabozantinib.
We are doing this study to learn if a new study drug called AMG-509 is safe and effective in men who have metastatic, castrate-resistant prostate cancer. AMG-509 is a type of drug that helps a type of immune cells called T cells find and kill prostate cancer cells.
The first part of this study will test different doses of AMG-509 in men, to learn what side effects the study drug causes and which doses are safe. The second part of the study will see if a safe dose of AMG-509 slows cancer growth.
This study will also teach us how long AMG-509 stays in your body, and whether treatment with AMG-509 changes the genes and proteins found in your tumor cells.
We are doing this study to find out how an experimental drug called sotorasib works in your body and against your cancer. We will compare how this drug works alone and in combination with several different drugs.
We are doing this study to collect symptom and treatment experience data from patients with acute myelogenous leukemia (AML) being seen at the Duke Cancer Institute. We will add this data to a data registry and use it to identify quality improvement opportunities.
If you choose to join this study, you will:
- Have tumor tissue from a biopsy sent to a lab for genetic testing
-- If the tumor tissue has a genetic change that is targeted by one or more of the study drugs being tested in this study, you may be assigned to that study.
We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.
We are doing this study to find out if an experimental drug called tabelecleucel is effective for the treatment of EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). We want to know if it is beneficial for people with EBV+PTLD who have received either a solid organ transplant or an allogeneic hematopoietic cell transplant.